CVS Caremark Corp. will pay $36.7 million to settle claims that it improperly switched patients from the tablet version of Zantac to a more expensive capsule version in order to increase Medicaid reimbursement, the U.S. Dept. of Justice announced.
The suit was originally brought as a whistleblower suit by Bernard Lisitza.
The federal share of the settlement is approximately $21.1 million. Twenty-three states and the District of Columbia will share $15.6 million pursuant to separate settlement agreements.